Rheumatoid Arthritis

FDA requires additional clinical data to determine the most appropriate doses of Olumiant (baricitinib) for the treatment of rheumatoid arthritis (RA).

Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity in RA.

The rheumatoid arthritis (RA) drug market is projected to reach approximately $28.5 billion by 2025.

Top five most popular articles this week on Specialty Pharmacy Times.

Heart failure higher among RA patients independent of their risk for ischemic heart disease.

Novel drug well-tolerated in patients with active RA who were refractory.

Synovial CD4+ T cells that produce IL-21 play a role in joint inflammation.

Efficacy of tocilizumab monotherapy was maintained or improved for up to 264 weeks.

More patients treated with baricitinib achieved ACR50 and ACR70 compared with Humira.

RA drug shows superiority compared with adalimumab and placebo.

Patients seeking treatment with the same drugs may face different out-of-pocket costs.

Azathioprine exposure linked to myeloid neoplasm.

Study opens doors for more precise RA treatments.

Top articles of the week on Specialty Pharmacy Times.

Aerobic exercise increases hematologic indices in patients with RA.

Smoking is a risk factor for breaking tolerance to multiple autoantigens in RA.

Scientists used a novel approach for imaging the movement of immune cells in mouse models of RA.

Targeting immune cells entering joints may prevent inflammatory arthritis.

TNFis improve the burden of comorbidity associated with RA.

Incidence of sleep apnea is 75% higher in patients with rheumatoid arthritis.

Certain factors influence the choice of the biologic drug in RA.

Humira is currently approved to treat rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

Treatment for rheumatoid arthritis carries numerous difficulties, from physical challenges to gaining access to new drugs.

Anti-TNFs reduce severity and incidence of myocardial infarction in RA patients.

Investigators identify factors that contribute to the chronic nature of autoimmune diseases.